PD-1 x VEGF/PD-L1 x VEGF 双特异性抗体:从产业角度进行业务、产品线和竞争分析
市场调查报告书
商品编码
1660107

PD-1 x VEGF/PD-L1 x VEGF 双特异性抗体:从产业角度进行业务、产品线和竞争分析

PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline and Competitor Analysis from an Industry Perspective

出版日期: | 出版商: La Merie Publishing | 英文 138 Pages | 订单完成后即时交付

价格
简介目录

Ivonescimab 是一种同类首创且目前同类最佳的PD-1xVEGF 双特异性抗体,由于其与抗 PD-1 Pembrolizumab(Keytruda)相比具有更优异的临床特性以及其许可协议的经济条款,为其管道竞争对手树立了标竿。与单独联合使用抗 PD-(L)1 和抗 VEGF 疗法相比,使用单一分子同时抑制 PD-1 和 VEGF( "协同作用" )可以改善安全性并增强抗肿瘤活性。具有第三种特异性的下一代三特异性 PD-(L)xVEGF 抗体可能会进一步提高临床益处。几乎所有研发的PD-(L)1xVEGF 抗体候选药物都来自致力于在中国进行开发的中国生物技术公司。这为西方生物製药公司在全球开发和行销方面建立策略联盟提供了机会。

本报告研究了 PD-1 x VEGF/PD-L1 x VEGF 双特异性抗体市场,并提供了截至2025年 2月的利害关係人、研发管道、临床概况、潜在候选药物的分子结构和商业交易的行业见解和分析。

报告中提到的公司

  • AcroImmune Biopharmaceutical
  • Akeso Biopharma
  • AP Biosciences
  • BioNTech
  • Biotheus
  • Bright Biologics
  • Crescent Biopharma
  • CStone Pharmaceuticals
  • DotBio
  • Genor Biopharma
  • Hangzhou Sumgen Biotech
  • HC Biopharma
  • ImmuneOnco Biopharmaceuticals
  • Instil Bio
  • LaNova Medicines
  • Merck & Co.
  • Minghui Pharmaceutical
  • NAYA Biosciences
  • OBI Pharma
  • OncoC4
  • OneGene Biotechnology
  • Ottimo Pharma
  • Paragon Therapeutics
  • RemeGen
  • Shanghai Huaota Biopharmaceutical
  • Shanghai Junshi Biosciences
  • Shenyang Sunshine Pharmaceutica (3SBio)
  • SinoCellTech Group
  • Summit Therapeutics
  • SyntBioTx
  • Tasly Pharmaceutical
  • UltraHuman Eight
  • Zhejiang Doer Biopharma

目录

产品描述

常见缩写

第1章 执行摘要

第2章 简介

第3章 PD-(L)1xVEGF 双特异性/三特异性管分析

  • 双特异性 PD-1xVEGF(R)抗体产品线
  • 双特异性 PD-L1xVEGF 抗体产品线
  • 三特异性 PD-L1xVEGF 抗体产品线

第4章 PD-(L)1xVEGF 双特异性抗体的临床经验

  • PD-1xVEGF抗体
    • Ivonescimab
    • MHB039A
  • PD-L1xVEGF抗体
    • HB0025
    • IMM2510
    • PM8002/BNT327

第5章 PD-(L)1xVEGF(R)双特异性/三特异性抗体的药物概况

  • PD-1xVEGF(R)双特异性抗体的药物概况
    • AI-081
    • CR-001
    • Ivonescimab
    • Jankistomig
    • JS207
    • LM-299
    • MHB0039A
    • NY-500
    • RC148
    • SCTB14
    • SSGJ-707
  • PD-L1xVEGF 双特异性抗体的药物概况
    • AP505,B1962
    • BB-203
    • HB0025
    • IMM2510,SYN-2510
    • PM8002,BNT327
    • SG1408
  • PD-(L1)xVEGF 三特异性抗体的药物概况
    • CS2009
    • DR30206
    • GB268
    • HC010
    • OGB2350

第6章 竞争与利害关係人分析

  • 处于高级开发阶段的PD-(L)1xVEGF 抗体利害关係人
  • PD-(L)1xVEGF 抗体在早期临床开发中的利害关係人
  • PD-(L)1xVEGF(R)抗体临床前研究与开发的利害关係人

第7章 PD-(L)1xVEGF 抗体业务公司简介

  • 3SBio
  • Akeso Biopharma
  • AP Biosciences
  • BioNTech
  • Biotheus
  • Bright Biologics
  • Crescent Biopharma
  • CStone Pharmaceuticals
  • Genor Biopharma
  • Hanzhou Sumgen Biotech
  • HC Biopharma
  • ImmuneOnco Biopharmaceuticals
  • Instil Bio
  • LaNova Medicines
  • Merck & Co
  • Minghui Pharmaceutical Co.
  • NAYA Biosciences
  • OncoC4
  • OneGen Biotechnology
  • Ottimo Pharma
  • RemeGen
  • Shanghai Huaota Biopharmaceutical
  • Shanghai Junshi Biosciences
  • SinoCellTech Group
  • Summit Therapeutics
  • Tasly Pharmaceutical
  • Zhejiang Doer Biopharma

第8章 PD-1/PD-L1 免疫肿瘤抗体市场

  • 市场概况
  • PD-1抗体市场
  • PD-L1抗体市场
  • 双特异性PD-1xCTLA-4/PD-1xLAG-3抗体市场
  • 其他尚无商业资讯的PD-(L1)抗体

第9章 商业交易:分拆、融资、许可、合併和收购以及估值

  • 衍生产品
  • 许可
  • 合併和收购
  • 估价

第10章 参考资料

简介目录
Product Code: LMFR0042

This report provides you with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective as of February 2025. The first-in-class and so far best-in-class PD-1xVEGF bispecific antibody ivonescimab has set the bar for competitors in the pipeline for a superior clinical profile compared with anti-PD-1 pembrolizumab (Keytruda) and for economic terms of the licensing agreement. The simultaneous blockade of PD-1 and VEGF ("cooperativity") by one molecule may produce enhanced antitumor activity with an improved safety profile compared with the co-administration of separate anti-PD-(L)1 and anti-VEGF therapies. A next generation of trispecific PD-(L)xVEGF antibodies with a third specificity may even further improve the clinical benefit. Nearly all of the PD-(L)1xVEGF antibody development candidates in the pipeline originate from Chinese biotechnology companies with focus on development in China. This provides an opportunity for Western biopharmaceutical companies for strategic collaborations in global development and marketing.

The report brings you up-to-date with information about and analysis of:

  • R&D pipeline of bispecific and trispecific PD-1xVEGF(R) and PD-L1xVEGF antibodies;
  • Molecular structure of PD-(L)1xVEGF(R) antibodies in development;
  • Preclinical and clinical profile of PD-(L)1xVEGF(R) antibodies;
  • Cancer indications in early development and in global development;
  • Clinical experience with PD-(L)1xVEGF antibodies;
  • Background profile of stakeholders (originator and licensee companies);
  • Competitor analysis;
  • Established market size for PD-1 and PD-L1 checkpoint inhibitor antibodies;
  • Business deals with economic terms: spin-offs, financing, licensing; mergers & acquisitions, company valuation.

In preclinical studies, anti-vascular endothelial growth factor (VEGF) and anti-PD-(L)1 antibodies were found to have synergistic antitumor activity. Anti-VEGF not only inhibits angiogenesis but also increases immune effector cell trafficking and infiltration into the tumor microenvironment, allowing for an immuno-responsive environment, which leads to enhanced efficacy of anti-PD-(L)1 inhibitors. Combining anti-PD-(L)1 antibodies with antiangiogenic agents was found to have antitumor activity and tolerable safety in advanced solid tumors. Clinical studies have shown that the combination of PD-(L)1 and VEGF antibodies significantly improves clinical benefit over PD-(L)1 antibody alone in certain settings.

To combine both targeting approaches, bispecific antibodies targeting PD-1 and VEGF by one molecule have been designed and preclinical studies showed that the combination in one molecule was superior to the combination of two separate molecules in antitumor activity.

As PD-1 and VEGF co-express in the tumor microenvironment, the dual-target design of a bispecific antibody combines PD-1 and VEGF to enable the enrichment and retention of macromolecular drugs in the tumor microenvironment, leading to a reduced distribution in the peripheral blood and a decreased toxicity caused by off-target effects.

Methodology:

This report evaluates the industry landscape of PD-1xVEGF(R) and PD-L1xVEGF bispecific and trispecific antibodies in research and development. The report provides a comprehensive overview of the R&D and partnering activities of pharmaceutical and technology companies in the field of PD-(L)1xVEGF(R) antibodies. This report is based on the identification and description of corporate stakeholders including biopharmaceutical companies and biotechnology companies. All publicly available information is fully referenced, either with scientific references (abstracts, posters, presentations, full paper) or hyperlinks leading to the source of information, such as press releases, corporate presentations, annual reports, SEC disclosures and homepage content.

Who will benefit from the report?

  • Business development and licensing (BDL) specialists;
  • Venture capital, private equity and investment managers;
  • Managers of Big Pharma venture capital firms;
  • Financial analysts;
  • CEO, COO and managing directors;
  • Corporate strategy analysts and managers;
  • Chief Technology Officer;
  • R&D Portfolio, Technology and Strategy Management;
  • Clinical and preclinical development specialists.

Companies Mentioned in the Report:

  • AcroImmune Biopharmaceutical
  • Akeso Biopharma
  • AP Biosciences
  • BioNTech
  • Biotheus
  • Bright Biologics
  • Crescent Biopharma
  • CStone Pharmaceuticals
  • DotBio
  • Genor Biopharma
  • Hangzhou Sumgen Biotech
  • HC Biopharma
  • ImmuneOnco Biopharmaceuticals
  • Instil Bio
  • LaNova Medicines
  • Merck & Co.
  • Minghui Pharmaceutical
  • NAYA Biosciences
  • OBI Pharma
  • OncoC4
  • OneGene Biotechnology
  • Ottimo Pharma
  • Paragon Therapeutics
  • RemeGen
  • Shanghai Huaota Biopharmaceutical
  • Shanghai Junshi Biosciences
  • Shenyang Sunshine Pharmaceutica (3SBio)
  • SinoCellTech Group
  • Summit Therapeutics
  • SyntBioTx
  • Tasly Pharmaceutical
  • UltraHuman Eight
  • Zhejiang Doer Biopharma

Table of Contents

Product Description

Table of Contents

Frequent Abbreviations

1. Executive Summary

2. Introduction

3. Analysis of PD-(L)1xVEGF bispecific and trispecific pipeline

  • 3.1. Pipeline of bispecific PD-1xVEGF(R) antibodies
  • 3.2. Pipeline of bispecific PD-L1xVEGF antibodies
  • 3.3. Pipeline of trispecific PD-L1xVEGF antibodies

4. Clinical Experience with PD-(L)1xVEGF Bispecific Antibodies

  • 4.1. PD-1xVEGF Antibodies
    • 4.1.1. Ivonescimab
    • 4.1.2. MHB039A
  • 4.2. PD-L1xVEGF Antibodies
    • 4.2.1. HB0025
    • 4.2.2. IMM2510
    • 4.2.3. PM8002/BNT327

5. PD-(L)1xVEGF(R) Bi- and Trispecific Antibody Drug Profiles

  • 5.1. PD-1xVEGF(R) Bispecific Antibody Drug Profiles
    • 5.1.1. AI-081
    • 5.1.2. CR-001
    • 5.1.3. Ivonescimab
    • 5.1.4. Jankistomig
    • 5.1.5. JS207
    • 5.1.6. LM-299
    • 5.1.7. MHB0039A
    • 5.1.8. NY-500
    • 5.1.9. RC148
    • 5.1.10. SCTB14
    • 5.1.11. SSGJ-707
  • 5.2. PD-L1xVEGF Bispecific Antibody Drug Profiles
    • 5.2.1. AP505; B1962
    • 5.2.2. BB-203
    • 5.2.3. HB0025
    • 5.2.4. IMM2510; SYN-2510
    • 5.2.5. PM8002; BNT327
    • 5.2.6. SG1408
  • 5.3. PD-(L1)xVEGF Trispecific Antibody Drug Profiles
    • 5.3.1. CS2009
    • 5.3.2. DR30206
    • 5.3.3. GB268
    • 5.3.4. HC010
    • 5.3.5. OGB2350

6. Competitor and Stakeholder Analysis

  • 6.1. Stakeholders with PD-(L)1xVEGF antibodies in advanced development
  • 6.2. Stakeholders with PD-(L)1xVEGF antibodies in early clinical development
  • 6.3. Stakeholders with PD-(L)1xVEGF(R) antibodies in non-clinical R&D

7. Profiles of Companies with PD-(L)1xVEGF Antibodies

  • 7.1 3SBio
  • 7.2. Akeso Biopharma
  • 7.3. AP Biosciences
  • 7.4. BioNTech
  • 7.5. Biotheus
  • 7.6. Bright Biologics
  • 7.7. Crescent Biopharma
  • 7.8. CStone Pharmaceuticals
  • 7.9. Genor Biopharma
  • 7.10. Hanzhou Sumgen Biotech
  • 7.11. HC Biopharma
  • 7.12. ImmuneOnco Biopharmaceuticals
  • 7.13. Instil Bio
  • 7.14. LaNova Medicines
  • 7.15. Merck & Co
  • 7.16. Minghui Pharmaceutical Co.
  • 7.17. NAYA Biosciences
  • 7.18. OncoC4
  • 7.19. OneGen Biotechnology
  • 7.20. Ottimo Pharma
  • 7.21. RemeGen
  • 7.22. Shanghai Huaota Biopharmaceutical
  • 7.23. Shanghai Junshi Biosciences
  • 7.24. SinoCellTech Group
  • 7.25. Summit Therapeutics
  • 7.26. Tasly Pharmaceutical
  • 7.27. Zhejiang Doer Biopharma

8. PD-1 and PD-L1 Immuno-Oncology Antibody Markets

  • 8.1. Market Overview
  • 8.2. PD-1 Antibody Market
  • 8.3. PD-L1 Antibody Market
  • 8.4. Bispecific PD-1xCTLA-4 and PD-1xLAG-3 Antibody Market
  • 8.5. Other PD-(L1) Antibodies without Information on Sales

9. Business Deals: spin-offs, financing, licensing, mergers & acquisitions, valuations

  • 9.1. Spin-offs
  • 9.2. Licensing
  • 9.3. Mergers & Acquisitions
  • 9.4. Valuation

10. References

Tables in the Report:

  • Table 1: Overview of PD-(L)1xVEGF(R) bi- and trispecific antibodies in the pipeline
  • Table 2: Overview bispecific PD-1 x VEGF(R2) antibodies
  • Table 3: Overview of structural features of PD-1xVEGF(R) antibodies
  • Table 4: Overview bispecific PD-L1 x VEGF antibodies
  • Table 5: Overview of structural features of PD-L1xVEGF antibodies
  • Table 6: Overview of trispecific PD-(L)1xVEGF antibodies
  • Table 7: Overview of structural features of PD-(L)1xVEGF trispecific antibodies
  • Table 8: Overview of major efficacy results in clinical phase II studies of ivonescimab
  • Table 9: Clinical indications of ivonescimab in phase III studies
  • Table 10: Overview of clinical studies with PM8002
  • Table 11: Overview of stakeholders with PD-(L)1xVEGF antibodies in advanced development
  • Table 12: Overview of Stakeholders with PD-(L)1xVEGF antibodies in early clinical development
  • Table 13: Overview of Stakeholders with PD-(L)1xVEGF antibodies in non-clinical R&D
  • Table 14: 2023 Total Sales of PD-1 & PD-L1 Antibodies per Class
  • Table 15: Sales & Growth Rates of PD-1 & PD-L1 Antibodies 2014-2023
  • Table 16: 2023 Individual Sales of Monospecific PD-1 Antibodies
  • Table 17: 2023 Individual Sales of Monospecific PD-L1 Antibodies
  • Table 18: 2023 Individual Sales of PD-L1 Antibody Combination Regimen
  • Table 19: 2023 Individual Sales of Bispecific or Combination PD-1 Antibodies
  • Table 20: Approved / Marketed PD-1 & PD-L1 Antibodies without Information on Sales
  • Table 21: Overview of business deals related to PD-(L)1 x VEGF(R) targeted bi- and trispecific antibody constructs
  • Table 22: Terms of Licensing Deals for PD-(L)1 x VEGF bispecific antibodies